Skip to main content
. 2022 Dec 16;11(24):4093. doi: 10.3390/cells11244093

Figure 9.

Figure 9

Disruption of lipid raft by MβCD and the effects on EGF-induced Akt phosphorylation. BT474 cells were treated with MβCD at various concentrations for 1 h to disrupt lipid raft. For the experiments with trastuzumab treatment, cells were incubated with trastuzumab and MβCD together for 1 h. Cells were then stimulated with EGF for 30 min. (A) CT-B stain (green) to show the disruption of lipid raft by MβCD. Cells were also stained with pHER2 (red). Line scan showed the intensities of CT-B and pHER2. (B) Dose-dependent effects of MβCD on Akt phosphorylation in BT474 breast cancer cells. Cells were treated with MβCD at indicated concentration for 4 h. The phosphorylation of Akt was then examined by immunoblotting. (C) Synergistic effects of trastuzumab and MβCD on Akt phosphorylation. Cells were treated with MβCD alone at 10 and 20 mM concentrations, or in combination with trastuzumab at 10 μg/mL. The phosphorylation of Akt was then examined by immunoblotting. *: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001.